Navigation Links
China PharmaHub Reviews 2010 and Recent Accomplishments
Date:3/24/2011

xchange Center ("STEC") in which China PharmaHub will represent the Sichuan government in seeking out biotechnology projects and the STEC will assist China PharmaHub and its partners in executing business ventures in Sichuan.
  • Continued collaboration with China's National Engineering Research Center ("NERC") for the Development of New Drugs as part of a 5-year exclusive collaboration. Under the agreement, China PharmaHub will identify drug candidates in the U.S., and also will assist the NERC in obtaining rights to develop and market these candidates in the People's Republic of China ("PRC"). In return, the NERC will identify drug candidates from the PRC for China PharmaHub to develop and market or out-license outside of the PRC and will assist in conducting the necessary preclinical and clinical studies in China with the State Food and Drug Administration ("SFDA") for selected worldwide drugs.
  • Entered into an agreement with Xiangxue Pharmaceutical to identify and pursue suitable projects for Xiangxue outside China. Furthermore, Xiangxue pledged to participate in the development and commercialization of certain products in Chinese markets, potentially CPC001.
  • Entered into an agreement with Chengdu Yunke Pharmaceutical in which China PharmaHub will obtain suitable projects for Chengdu Yunke outside the Greater China Region.
  • Entered an agreement with Guangzhou Baidi Biotechnology to identify suitable projects for Guangzhou Baidi Biotechnology outside China. In addition, both parties agreed to collaborate on the research and development of the Epidermal Growth Factor Receptor (EGFR) humanized antibody platform.
  • Entered into a letter of intent with Chengdu Gaotong Isotope to jointly promote CPC001, an irradiated microsphere device to treat liver cancer, in China.
  • Authorized by Chengdu Yongkon Pharmaceutical as its appointed agent to identify pharmaceutical products and medical devices in the U.S. and negotiate the terms t
    '/>"/>

  • SOURCE China PharmaHub Corp.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related biology technology :

    1. ACT to Be Issued Broad Patent for Human ES Cell-derived RPE Cells in China
    2. China PharmaHub In-Licenses Universal Donor Red Blood Cells Technology Exclusively From University of California, San Diego
    3. China-Biotics Expands Product Supplied to Bright Dairy
    4. Huifeng Bio-Pharmaceutical Technology, Inc. to Present at the 2011 Rodman & Renshaw Annual China Investment Conference in Shanghai
    5. China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results
    6. ShengdaTech to Present at Rodman & Renshaw Annual China Investment Conference in Shanghai
    7. China Cord Blood Corporation Forms Zhejiang Subsidiary
    8. China Cord Blood Corporation Announces Results of 2010 Annual General Meeting
    9. China Cord Blood Corporation to Announce Third Quarter Fiscal 2011 Financial Results
    10. China-Biotics to Report Fiscal Year 2011 Third Quarter Financial Results on February 9
    11. China-Biotics, Inc. Provides Preliminary FY2011Third Quarter Revenue
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/28/2015)... , July 29, 2015 A ... acquiring, rapidly developing and commercialising innovative medicines ...   Highly experienced management team; blue chip ...   Mereo BioPharma Group Ltd ("Mereo"), a ... $119m ( c. £76.5m), gross, from blue chip institutional ...
    (Date:7/28/2015)... July 28, 2015 Seahorse Bioscience, the ... is the provider of XF Technology which is ... research areas. As the links between mitochondrial function ... metabolism is escalating rapidly.   Recently, ... Nature Publishing Group (NPG) featuring XF Technology, including ...
    (Date:7/28/2015)... YORK , July 28, 2015 Deerfield ... Deerfield Healthcare Innovations Fund, L.P., which will invest in ... interventions in genetic diseases, cancer, and orphan diseases. The ... can transform how therapeutics are developed and improve the ... fund, one of the largest healthcare-focused venture funds in ...
    (Date:7/28/2015)... , July 28, 2015 CSL ... Drug Administration has accepted for review the company,s Biologics ... VIII single-chain (rVIII-SingleChain) for the treatment of hemophilia A. ... endpoints. Hemophilia A is ... factor VIII; nearly all affected patients are male. People ...
    Breaking Biology Technology:Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 2Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 3Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 4Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 5Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 6Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 7Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 8Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 9Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 10Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 11XF Technology Used to Demonstrate Feasibility of Stem Cell Regenerative Technique 2XF Technology Used to Demonstrate Feasibility of Stem Cell Regenerative Technique 3Deerfield Launches $550 Million Healthcare Venture-Capital Fund 2Deerfield Launches $550 Million Healthcare Venture-Capital Fund 3U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 3
    ... UOP LLC, a Honeywell (NYSE: HON ... for use in Rentech, Inc.,s Rialto Renewable Energy Center ... The renewable energy center, to be built in ... tree trimmings, into renewable, ultra-clean diesel fuel and renewable ...
    ... 1 PDL BioPharma, Inc. (PDL) (Nasdaq: ... quarter ended September 30, 2010 of approximately $86 million, ... the third quarter of 2009, a 20 percent year-over-year ... quarter 2010 sales of Avastin®, Herceptin®, Lucentis® and Tysabri® ...
    ... cotton cloth in a high-tech broth full of silver nanowires ... low-cost filter that could easily be implemented to purify water ... bacteria as most existing filters do, the new filter lets ... time the pathogens have passed through, they have also passed ...
    Cached Biology Technology:Honeywell UOP Technology Selected to Support Conversion of Biomass to Fuel at California Renewable Energy Facility 2Honeywell UOP Technology Selected to Support Conversion of Biomass to Fuel at California Renewable Energy Facility 3PDL BioPharma Provides Third Quarter 2010 Revenue Guidance of Approximately $86 Million and Update to its Correspondence With Genentech 2PDL BioPharma Provides Third Quarter 2010 Revenue Guidance of Approximately $86 Million and Update to its Correspondence With Genentech 3PDL BioPharma Provides Third Quarter 2010 Revenue Guidance of Approximately $86 Million and Update to its Correspondence With Genentech 4PDL BioPharma Provides Third Quarter 2010 Revenue Guidance of Approximately $86 Million and Update to its Correspondence With Genentech 5High-speed filter uses electrified nanostructures to purify water at low cost 2High-speed filter uses electrified nanostructures to purify water at low cost 3High-speed filter uses electrified nanostructures to purify water at low cost 4
    (Date:7/21/2015)... 21, 2015 Today, ZTE announced its Android ... well as expected revenues in 2015 that relate to sales of ... guidance of approximately 2,200 MSEK for 2015. Jörgen Lantto, ... smartphone manufacturer in China and we are ... 5 for Axon , its ...
    (Date:7/20/2015)... DENVER , July 20, 2015  Acuity ... Mobility Report: The Convergence of Commerce and Privacy" ... billion mobile biometric apps will be downloaded to ... users. The mobile biometrics market is projected to ... app revenue during the seven-year forecast period.    ...
    (Date:7/9/2015)... July 9, 2015  Synaptics Inc. (NASDAQ: SYNA ), ... that it will report financial results for the fourth ... 2015 after the close of market. The company will ... at 2:00 p.m. PT (5:00 p.m. ET), during which ... participate on the live call, analysts and investors should ...
    Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2
    ... is good news for coffee lovers and growers worldwide: A ... discovered in Africa. Looking at coffee berries in Western Kenya, ... and Ecology in Kenya, Dr. Eric Chapman from the University ... thrips* Karnyothrips flavipes which feeds on ...
    ... a gene activity signature that predicts a high risk ... been treated with commonly used chemotherapy drugs. Despite ... breast cancers bearing this gene signature will probably still ... scientists in a letter to be published in ...
    ... N.Y. (January 21, 2010) Two recent, separate publications identified ... or clusters in California. Using data collected ... 2.5 million births including almost 10,000 autism cases from ... of elevated risk for autism. Autism Speaks, the ...
    Cached Biology News:Natural pest control saves coffee berry 2Genes found linked to breast cancer drug resistance could guide future treatment choices 2Genes found linked to breast cancer drug resistance could guide future treatment choices 3Genes found linked to breast cancer drug resistance could guide future treatment choices 4Autism Speaks responds to recent publications citing autism clusters in California 2
    ...
    Water Distilled (Gibco™) is membrane filtered and endotoxin screened....
    Immunogen: Human Respiratory Syncytial Virus (RSV) and Bovine Respiratory Syncytial Virus (BRSV) Fusion protein Storage: -20 C, Avoid Freeze/Thaw Cycles...
    Mus musculus MARCKS-like protein, mRNA...
    Biology Products: